Apoha raises $36m led by Singular to build a molecular data platform
Singular led the funding round, with participation from Draper Associates and seed investors.
≈ £26.8M at $1 = £0.7447 on 3 Jun 2026
Apoha develops a biophysical data platform that measures molecular and material behaviour to help industries assess candidate viability.
Apoha has raised $36m in funding led by Singular to commercialise its molecular behaviour platform. The round includes participation from Draper Associates alongside existing backers Redalpine, Seedcamp, Wilbe and Nucleus, supplemented by grant funding from Innovate UK.
The London and San Francisco-based company plans to use the capital to scale its platform, which measures how molecules and materials behave under real-world conditions. The technology has already been adopted by partners including Boehringer Ingelheim to screen antibody candidates.
The fresh capital arrives as the firm emerges from stealth, backed by foundational research from Oxford and commercial expertise from the financial sector.
From the founder
"Liquid State Intelligence took 15 years of science and 5 years of company-building to bring to life,"
Shamit Shrivastava
CEO at Apoha
Investor perspective
"Apoha represents a new generation of European scientific companies where AI is not a future promise, but a practical tool already transforming how biology is done. For the first time in 25 years, we are back to creating genuinely new science, being commercialised by founders with drive and global ambition."
Raffi Kamber
Co-Founder and GP, Singular
